Anwar Michael Badruddoja, MD
Neurology · Tucson, AZNPI 1891779872
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (35.6%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 36 manufacturers reported payments, led by Biogen at 48.6% of the total. Reporting peaked in 2021 at $5,446 and has fallen 84.0% since, to $869 in 2025.
Across 147 payments — averaging $97.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biogen$7K
- E.r. Squibb & Sons, L.L.C.$2K
- Genentech, Inc.$2K
- Eisai Inc.$1K
- AbbVie$356
- Novartis$227
- plus $2K from 30 others
Across 103 payments — averaging $13,813 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$867K
- Genentech, Inc.$255K
- Biogen$163K
- E.r. Squibb & Sons, L.L.C.$103K
- Eisai Inc.$24K
- Beigene, Ltd.$8K
- plus $3K from 1 others
What the payments were for
- Consulting fees$2,82520%
- Speaking & faculty fees$5,08536%
- Travel & lodging$2,80820%
- Food & beverage$3,45924%
- Education$1161%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biogen | 29 | $6,944 |
| E.r. Squibb & Sons, L.L.C. | 3 | $1,926 |
| Genentech, Inc. | 1 | $1,695 |
| Eisai Inc. | 11 | $1,398 |
| AbbVie | 15 | $356 |
| Novartis | 12 | $227 |
| Amgen | 9 | $192 |
| Novocure Inc. | 1 | $147 |
| Silk Road Medical, Inc. | 1 | $142 |
| UCB, Inc. | 5 | $127 |
| Vanda Pharmaceuticals Inc. | 5 | $127 |
| Arbor Pharmaceuticals, Inc. | 5 | $118 |
| Sanofi | 4 | $101 |
| EMD Serono, Inc. | 4 | $82 |
| Pfizer | 5 | $75 |
| Argenx US, Inc. | 3 | $61 |
| Sumitomo Pharma America, Inc. | 6 | $55 |
| Jazz Pharmaceuticals Inc. | 2 | $54 |
| Bristol Myers Squibb | 3 | $49 |
| Servier Pharmaceuticals LLC | 2 | $46 |
| Lilly USA, LLC | 3 | $43 |
| TG Therapeutics, Inc. | 2 | $41 |
| Cycle Pharmaceuticals Inc | 2 | $37 |
| GT Medical Technologies, Inc | 1 | $35 |
| Neurocrine Biosciences, Inc. | 2 | $34 |
| Impel Pharmaceuticals Inc. | 1 | $24 |
| Acadia Pharmaceuticals Inc | 1 | $23 |
| Mallinckrodt Hospital Products Inc. | 1 | $17 |
| Bayer | 1 | $17 |
| Catalyst Pharmaceuticals, Inc. | 1 | $17 |
| Lundbeck LLC | 1 | $16 |
| Kyowa Kirin, Inc. | 1 | $16 |
| Amneal Pharmaceuticals LLC | 1 | $15 |
| Merz Pharmaceuticals, LLC | 1 | $14 |
| AstraZeneca | 1 | $14 |
| Aucta Pharmaceuticals, Inc. | 1 | $7 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,292 in reported general payments places this provider in the 75th percentile of 388 neurology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AubagioTeriflunomide | 16 | $149,978 |
| Avonex (4 Pack)Interferon Beta-1a | 13 | $124,714 |
| TecfideraDimethyl Fumarate | 13 | $120,817 |
| ZonegranZonisamide | 17 | $115,413 |
| Glatiramer Acetate | 40 | $87,355 |
| BriviactBrivaracetam | 41 | $80,269 |
| VimpatLacosamide | 40 | $53,567 |
| Nurtec OdtRimegepant Sulfate | 29 | $42,551 |
| KeppraLevetiracetam | 19 | $34,580 |
| XcopriCenobamate | 19 | $29,752 |
| LamictalLamotrigine | 13 | $28,134 |
| Aimovig AutoinjectorErenumab-Aooe | 15 | $23,233 |
| UbrelvyUbrogepant | 20 | $19,407 |
| Rufinamide | 12 | $18,390 |
| Lacosamide | 116 | $17,984 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BiogenAvonex (4 Pack), Tecfidera | $6,944 | $245,53126 claims |
| SanofiAubagio | $101 | $149,97816 claims |
| UCB, Inc.Briviact, Vimpat | $127 | $133,83781 claims |
| PfizerNurtec Odt, Eliquis, Dilantin | $75 | $59,92470 claims |
| AbbVieUbrelvy | $356 | $19,40720 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 388 neurology providers in Arizona.
Other neurology in Tucson
- Francisco ValdiviaTucson$137K
- Cynthia ReedTucson$111K
- Yeeck SimTucson$38K
- Barry HendinPhoenix$2.3M
- Maria OspinaPhoenix$2.1M
- Suraj MuleyPhoenix$1.7M
- Nida LaurinScottsdale$969K
- Eric ErossPhoenix$778K
- Steve ChungPhoenix$685K
- Marwan SabbaghPhoenix$603K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.